Redirecting coronavirus to a nonnative receptor through a virus-encoded targeting adapter

Journal of Virology

Volumn 80, Issue 3, 2006, Pages 1250-1260

  Verheije, M H ^a,b   Wurdinger T ^a,b   Van Beusechem, V W ^b   De Haan, C A M ^a   Gerritsen, W R ^b   Rottier, P J M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTER PROTEIN; ADAPTOR PROTEIN; CELL RECEPTOR; HISTIDINE; MURINE CARCINOEMBRYONIC ANTIGEN CELL ADHESION PROTEIN 1A; UNCLASSIFIED DRUG; VIRUS SPIKE PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CELL DEATH; CELL FUSION; CELL KILLING; CONTROLLED STUDY; CORONAVIRUS; GENE CASSETTE; HUMAN; HUMAN CELL; INFECTION SENSITIVITY; INOCULATION; MOLECULAR RECOGNITION; MOUSE; MURINE HEPATITIS CORONAVIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGENY; PROTEIN PROTEIN INTERACTION; RNA RECOMBINATION; TARGET CELL; VIROGENESIS; VIRUS GENOME; VIRUS INFECTION; VIRUS RECOMBINANT;

ANIMALS; BASE SEQUENCE; BINDING SITES; CARCINOEMBRYONIC ANTIGEN; CATS; CELL LINE; DNA, RECOMBINANT; GENE PRODUCTS, VIF; HUMANS; MEMBRANE FUSION; MEMBRANE GLYCOPROTEINS; MICE; MURINE HEPATITIS VIRUS; RECEPTORS, VIRUS; RECOMBINANT PROTEINS; VIRAL ENVELOPE PROTEINS; VIRUS REPLICATION;

ANIMALIA; CORONAVIRUS; MURINAE; MURINE HEPATITIS VIRUS;

EID: 31144450269     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.80.3.1250-1260.2006     Document Type: Article

References (58)

1. Beauchemin, N., P. Draber, G. Dveksler, P. Gold, S. Gray-Owen, F. Grunert, S. Hammarstrom, K. V. Holmes, A. Karlsson, M. Kuroki, S. H. Lin, L. Lucka, S. M. Najjar, M. Neumaier, B. Obrink, J. E. Shively, K. M. Skubitz, C. P. Stanners, P. Thomas, J. A. Thompson, M. Virji, S. von Kleist, C. Wagener, S. Watt, and W. Zimmermann. 1999. Redefined nomenclature for members of the carcinoembryonic antigen family. Exp. Cell Res. 252:243-249.
2. Bosch, B. J., R. van der Zee, C. A. de Haan, and P. J. Rottier. 2003. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J. Virol. 77:8801-8811.
3. de Haan, C. A., P. S. Masters, X. Shen, S. Weiss, and P. J. Rottier. 2002. The group-specific murine coronavirus genes are not essential, but their deletion, by reverse genetics, is attenuating in the natural host. Virology 296:177-189.
4. de Haan, C. A., L. van Genne, J. N. Stoop, H. Volders, and P. J. Rottier. 2003. Coronaviruses as vectors: position dependence of foreign gene expression. J. Virol. 77:11312-11323.
5. de Haan, C. A., H. Volders, C. A. Koetzner, P. S. Masters, and P. J. Rottier. 2002. Coronaviruses maintain viability despite dramatic rearrangements of the strictly conserved genome organization. J. Virol. 76:12491-12502.
6. Dmitriev, I., E. Kashentseva, B. E. Rogers, V. Krasnykh, and D. T. Curiel. 2000. Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J. Virol. 74:6875-6884.
7. Dmitriev, I., V. Krasnykh, C. R. Miller, M. Wang, E. Kashentseva, G. Mikheeva, N. Belousova, and D. T. Curiel. 1998. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. 72:9706-9713.
8. Douglas, J. T., C. R. Miller, M. Kim, I. Dmitriev, G. Mikheeva, V. Krasnykh, and D. T. Curiel. 1999. A system for the propagation of adenoviral vectors with genetically modified receptor specificities. Nat. Biotechnol. 17:470-475.
9. Dveksler, G. S., C. W. Dieffenbach, C. B. Cardellichio, K. McCuaig, M. N. Pensiero, G.-S. Jiang, N. Beauchemin, and K. V. Holmes. 1993. Several members of the mouse carcinoembryonic antigen-related glycoprotein family are functional receptors for the coronavirus mouse hepatitis virus-A59. J. Virol. 67:1-8.
10. Dveksler, G. S., S. E. Gagneten, C. A. Scanga, C. B. Cardellichio, and K. V. Holmes. 1996. Expression of the recombinant anchorless N-terminal domain of mouse hepatitis virus (MHV) receptor makes hamster or human cells susceptible to MHV infection. J. Virol. 70:4142-4145.
11. Dveksler, G. S., M. N. Pensiero, C. B. Cardellichio, R. K. Williams, G. S. Jiang, K. V. Holmes, and C. W. Dieffenbach. 1991. Cloning of the mouse hepatitis virus (MHV) receptor: expression in human and hamster cell lines confers susceptibility to MHV. J. Virol. 65:6881-6891.
12. Dveksler, G. S., M. N. Pensiero, C. W. Dieffenbach, C. B. Cardellichio, A. A. Basile, P. E. Elia, and K. V. Holmes. 1993. Mouse hepatitis virus strain A59 and blocking antireceptor monoclonal antibody bind to the N-terminal domain of cellular receptor. Proc. Natl. Acad. Sci. USA 90:1716-1720.
13. Fuerst, T. R., E. G. Niles, F. W. Studier, and B. Moss. 1986. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc. Natl. Acad. Sci. USA 83:8122-8126.
14. Gagneten, S., O. Gout, M. Dubois-Dalcq, P. Rottier, J. Rossen, and K. V. Holmes. 1995. Interaction of mouse hepatitis virus (MHV) spike glycoprotein with receptor glycoprotein MHVR is required for infection with an MHV strain that expresses the hemagglutinin-esterase glycoprotein. J. Virol. 69:889-895.
15. Gallagher, T. M. 1997. A role for naturally occurring variation of the murine coronavirus spike protein in stabilizing association with the cellular receptor. J. Virol. 71:3129-3137.
16. Gallagher, T. M., M. J. Buchmeier, and S. Perlman. 1992. Cell receptor-independent infection by a neurotropic murine coronavirus. Virology 191:517-522.
17. Hallak, L. K., J. R. Merchan, C. M. Storgard, J. C. Loftus, and S. J. Russell. 2005. Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression. Cancer Res. 65:5292-5300.
18. Hammond, A. L., R. K. Plemper, J. Zhang, U. Schneider, S. J. Russell, and R. Cattaneo. 2001. Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J. Virol. 75:2087-2096.
19. Hay, C. M., H. De Leon, J. D. Jafari, J. L. Jakubczak, C. A. Mech, P. L. Hallenbeck, S. K. Powell, G. Liau, and S. C. Stevenson. 2001. Enhanced gene transfer to rabbit jugular veins by an adenovirus containing a cyclic RGD motif in the HI loop of the fiber knob. J. Vasc. Res. 38:315-323.
20. Hemminki, A., M. Wang, T. Hakkarainen, R. A. Desmond, J. Wahlfors, and D. T. Curiel. 2003. Production of an EGFR targeting molecule from a conditionally replicating adenovirus impairs its oncolytic potential. Cancer Gene Ther. 10:583-588.
21. Katane, M., E. Takao, Y. Kubo, R. Fujita, and H. Amanuma. 2002. Factors affecting the direct targeting of murine leukemia virus vectors containing peptide ligands in the envelope protein. EMBO Rep. 3:899-904.
22. Kim, J., T. Smith, N. Idamakanti, K. Mulgrew, M. Kaloss, H. Kylefjord, P. C. Ryan, M. Kaleko, and S. C. Stevenson. 2002. Targeting adenoviral vectors by using the extracellular domain of the coxsackie-adenovirus receptor: improved potency via trimerization. J. Virol. 76:1892-1903.
23. Krasnykh, V., I. Dmitriev, G. Mikheeva, C. R. Miller, N. Belousova, and D. T. Curiel. 1998. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J. Virol. 72:1844-1852.
24. Krasnykh, V. N., J. T. Douglas, and V. W. van Beusechem. 2000. Genetic targeting of adenoviral vectors. Mol. Ther. 1:391-405.
25. Kubo, H., Y. K. Yamada, and F. Taguchi. 1994. Localization of neutralizing epitopes and the receptor-binding site within the amino-terminal 330 amino acids of the murine coronavirus spike protein. J. Virol. 68:5403-5410.
26. Kuo, L., G. J. Godeke, M. J. Raamsman, P. S. Masters, and P. J. Rottier. 2000. Retargeting of coronavirus by substitution of the spike glycoprotein ectodomain: crossing the host cell species barrier. J. Virol. 74:1393-1406.
27. Lindner, P., K. Bauer, A. Krebber, L. Nieba, E. Kremmer, C. Krebber, A. Honegger, B. Klinger, R. Mocikat, and A. Pluckthun. 1997. Specific detection of his-tagged proteins with recombinant anti-His tag scFv-phosphatase or scFv-phage fusions. BioTechniques 22:140-149.
28. Matsuyama, S., and F. Taguchi. 2002. Receptor-induced conformational changes of murine coronavirus spike protein. J. Virol. 76:11819-11826.
29. Michael, S. I., J. S. Hong, D. T. Curiel, and J. A. Engler. 1995. Addition of a short peptide ligand to the adenovirus fiber protein. Gene Ther. 2:660-668.
30. Miura, H. S., K. Nakagaki, and F. Taguchi. 2004. N-terminal domain of the murine coronavirus receptor CEACAM1 is responsible for fusogenic activation and conformational changes of the spike protein. J. Virol. 78:216-223.
31. Nakano, K., R. Asano, K. Tsumoto, H. Kwon, W. F. Goins, I. Kumagai, J. B. Cohen, and J. C. Glorioso. 2005. Herpes simplex virus targeting to the EGF receptor by a gD-specific soluble bridging molecule. Mol. Ther. 11:617-626.
32. Nedellec, P., G. S. Dveksler, E. Daniels, C. Turbide, B. Chow, A. A. Basile, K. V. Holmes, and N. Beauchemin. 1994. Bgp2, a new member of the carcinoembryonic antigen-related gene family, encodes an alternative receptor for mouse hepatitis viruses. J. Virol. 68:4525-4537.
33. Nicklin, S. A., and A. H. Baker. 2002. Tropism-modified adenoviral and adeno-associated viral vectors for gene therapy. Curr. Gene Ther. 2:273-293.
34. Ohtsuka, N., Y. K. Yamada, K. Saeki, and F. Taguchi. 1998. Differential receptor-functionality of the two distinct receptor proteins for mouse hepatitis virus. Adv. Exp. Med. Biol. 440:77-80.
35. Ohtsuka, N., Y. K. Yamada, and F. Taguchi. 1996. Difference in virus-binding activity of two distinct receptor proteins for mouse hepatitis virus. J. Gen. Virol. 77:1683-1692.
36. Peng, K. W., K. A. Donovan, U. Schneider, R. Cattaneo, J. A. Lust, and S. J. Russell. 2003. Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. Blood 101:2557-2562.
37. Peng, K. W., and S. J. Russell. 1999. Viral vector targeting. Curr. Opin. Biotechnol. 10:454-457.
38. Rao, P. V., and T. M. Gallagher. 1998. Mouse hepatitis virus receptor levels influence virus-induced cytopathology. Adv. Exp. Med. Biol. 440:549-555.
39. Rao, P. V., S. Kumari, and T. M. Gallagher. 1997. Identification of a contiguous 6-residue determinant in the MHV receptor that controls the level of virion binding to cells. Virology 229:336-348.
40. Ries, S. J., and C. H. Brandts. 2004. Oncolytic viruses for the treatment of cancer: current strategies and clinical trials. Drug Discov. Today 9:759-768.
41. Rottier, P. J., M. C. Horzinek, and B. A. van der Zeijst. 1981. Viral protein synthesis in mouse hepatitis virus strain A59-infected cells: effect of tunicamycin. J. Virol. 40:350-357.
42. Saeki, K., N. Ohtsuka, and F. Taguchi. 1998. Isolation and characterization of murine coronavirus mutants resistant to neutralization by soluble receptors. Adv. Exp. Med. Biol. 440:11-16.
43. Schneider, U., F. Bullough, S. Vongpunsawad, S. J. Russell, and R. Cattaneo. 2000. Recombinant measles viruses efficiently entering cells through targeted receptors. J. Virol. 74:9928-9936.
44. Shi, W., and J. S. Bartlett. 2003. RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7:515-525.
45. Stevenson, S. C., M. Rollence, J. Marshall-Neff, and A. McClelland. 1997. Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein. J. Virol. 71:4782-4790.
46. Sturman, L. S., C. S. Ricard, and K. V. Holmes. 1985. Proteolytic cleavage of the E2 glycoprotein of murine coronavirus: activation of cell-fusing activity of virions by trypsin and separation of two different 90K cleavage fragments. J. Virol. 56:904-911.
47. Taguchi, F., and S. Matsuyama. 2002. Soluble receptor potentiates receptor-independent infection by murine coronavirus. J. Virol. 76:950-958.
48. Tan, K., B. D. Zelus, R. Meyers, J. H. Liu, J. M. Bergelson, N. Duke, R. Zhang, A. Joachimiak, K. V. Holmes, and J. H. Wang. 2002. Crystal structure of murine sCEACAM1a[1,4]: a coronavirus receptor in the CEA family. EMBO J. 21:2076-2086.
49. Tsai, J. C., B. D. Zelus, K. V. Holmes, and S. R. Weiss. 2003. The N-terminal domain of the murine coronavirus spike glycoprotein determines the CEA CAM1 receptor specificity of the virus strain. J. Virol. 77:841-850.
50. Vennema, H., L. Heijnen, A. Zijderveld, M. C. Horzinek, and W. J. Spaan. 1990. Intracellular transport of recombinant coronavirus spike proteins: implications for virus assembly. J. Virol. 64:339-346.
51. Wessner, D. R., P. C. Shick, J. H. Lu, C. B. Cardellichio, S. E. Gagneten, N. Beauchemin, K. V. Holmes, and G. S. Dveksler. 1998. Mutational analysis of the virus and monoclonal antibody binding sites in MHVR, the cellular receptor of the murine coronavirus mouse hepatitis virus strain A59. J. Virol. 72:1941-1948.
52. Williams, R. K., G. S. Jiang, and K. V. Holmes. 1991. Receptor for mouse hepatitis virus is a member of the carcinoembryonic antigen family of glycoproteins. Proc. Natl. Acad. Sci. USA 88:5533-5536.
53. Würdinger, T., M. H. Verheije, K. Broen, B. J. Bosch, B. J. Haijema, C. A. M. de Haan, V. W. van Beusechem, W. R. Gerritsen, and P. J. M. Rottier. 2005. Soluble receptor-mediated targeting of mouse hepatitis coronavirus to the human epidermal growth factor receptor. J. Virol. 79:15314-15322.
54. Würdinger, T., M. H. Verheije, M. Raaben, B. J. Bosch, C. A. M. de Haan, V. W. van Beusechem, P. J. M. Rottier, and W. R. Gerritsen. 2005. Targeting non-human coronaviruses to human cancer cells using a bispecific single-chain antibody. Gene Ther. 12:1394-1404.
55. Yokomori, K., and M. M. Lai. 1992. Mouse hepatitis virus utilizes two carcinoembryonic antigens as alternative receptors. J. Virol. 66:6194-6199.
56. Zelus, B. D., J. H. Schickli, D. M. Blau, S. R. Weiss, and K. V. Holmes. 2003. Conformational changes in the spike glycoprotein of murine coronavirus are induced at 37°C either by soluble murine CEACAM1 receptors or by pH 8. J. Virol. 77:830-840.
57. Zelus, B. D., D. R. Wessner, G. S. Dveksler, and K. V. Holmes. 1998. Neutralization of MHV-A59 by soluble recombinant receptor glycoproteins. Adv. Exp. Med. Biol. 440:3-9.
58. b, and Bgp2 murine coronavirus receptors differ in mouse hepatitis virus binding and neutralizing activities. J. Virol. 72:7237-7244.